Hybrid Cf
NDC 49804-101
Product Information
Hybrid Cf is a OTC MONOGRAPH FINAL-approved product labeled by Hybrid-rx Llc. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a yellow product. This product entry covers the primary NDC 49804-101 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
PAC
Code Structure Chart
Product Details
What is NDC 49804-101?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- ACETAMINOPHEN (UNII: 362O9ITL9D)
- ACETAMINOPHEN (UNII: 362O9ITL9D) (Active Moiety)
- PHENYLEPHRINE HYDROCHLORIDE (UNII: 04JA59TNSJ)
- PHENYLEPHRINE (UNII: 1WS297W6MV) (Active Moiety)
- CHLORPHENIRAMINE MALEATE (UNII: V1Q0O9OJ9Z)
- CHLORPHENIRAMINE (UNII: 3U6IO1965U) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)
- FD&C YELLOW NO. 6 (UNII: H77VEI93A8)
- HYPROMELLOSE 2910 (15 CPS) (UNII: 36SFW2JZ0W)
- TRIACETIN (UNII: XHX3C3X673)
- POVIDONE (UNII: FZ989GH94E)
- STEARIC ACID (UNII: 4ELV7Z65AP)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1052679 - acetaminophen 500 MG / chlorpheniramine maleate 2 MG / phenylephrine HCl 5 MG Oral Tablet
- RxCUI: 1052679 - acetaminophen 500 MG / chlorpheniramine maleate 2 MG / phenylephrine hydrochloride 5 MG Oral Tablet
- RxCUI: 1052679 - APAP 500 MG / Chlorpheniramine Maleate 2 MG / Phenylephrine Hydrochloride 5 MG Oral Tablet
* Please review the full disclaimer at the bottom of this page.